Table of contents

Extended reports

• Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis (25 May, 2007)

  J Larghero, D Farge, A Braccini, S Lecourt, A Scherberich, E Foïs, F Verrecchia, T Daikeler, E Gluckman, A Tyndall, C Bocelli-Tyndall
• Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls (2 August, 2007)

  A M Jacobi, D M Goldenberg, F Hiepe, A Radbruch, G R Burmester, T Dörner
• Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus (24 August, 2007) Free

  A H Sawalha, K M Kaufman, J A Kelly, A J Adler, T Aberle, J Kilpatrick, E K Wakeland, Q-Z Li, A E Wandstrat, D R Karp, J A James, J T Merrill, P Lipsky, J B Harley
• Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic (20 August, 2007)

  A Mor, C O Bingham, M Kishimoto, P M Izmirly, J D Greenberg, S Reddy, P B Rosenthal
• Associations between genetic factors, tobacco smoking and autoantibodies in familial and sporadic rheumatoid arthritis (27 July, 2007)

  L Michou, V H Teixeira, C Pierlot, S Lasbleiz, T Bardin, P Dieudé, B Prum, F Cornélis, E Petit-Teixeira
• Varus–valgus motion and functional ability in patients with knee osteoarthritis (29 June, 2007)

  M van der Esch, M Steultjens, J Harlaar, N Wolterbeek, D Knol, J Dekker
• A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis (2 August, 2007)

  C Miceli-Richard, E Comets, C Verstuyft, R Tamouza, P Loiseau, P Ravaud, H Kupper, L Becquemont, D Charron, X Mariette
• –463 G/A myeloperoxidase promoter polymorphism in giant cell arteritis (17 August, 2007)

  C Salvarani, B Casali, E Farnetti, N Pipitone, D Nicoli, P L Macchioni, L Cimino, G L Bajocchi, M G Catanoso, L Pattacini, A Ghinoi, G Restuccia, L Boiardi
• Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions (29 August, 2007)

  D van der Heijde, R Landewé, E Feldtkeller
• Individualising the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) function subscale: incorporating patient priorities for improvement to measure functional impairment in hip or knee osteoarthritis (17 August, 2007)

  R Seror, F Tubach, G Baron, B Falissard, I Logeart, M Dougados, P Ravaud
• Systemic lupus erythaematosus in a multiethnic US cohort (LUMINA) LIII: disease expression and outcome in acute onset lupus (24 August, 2007)

  A M Bertoli, L M Vilá, J D Reveille, G S Alarcón, for the LUMINA study group
• Change in self-reported outcomes and objective physical function over 7 years in middle-aged subjects with or at high risk of knee osteoarthritis (17 August, 2007)

  E M Roos, A B Bremander, M Englund, L S Lohmander
• Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab (20 July, 2007)

  S Visvanathan, C Wagner, J C Marini, D Baker, T Gathany, J Han, D van der Heijde, J Braun
• The phosphorycholine moiety of the filarial nematode immunomodulator ES-62 is responsible for its anti-inflammatory action in arthritis (17 August, 2007) Free

  M M Harnett, D E Kean, A Boitelle, S McGuiness, T Thalhamer, C N Steiger, C Egan, L Al-Riyami, M J Alcocer, K M Houston, J A Gracie, I B McInnes, W Harnett
• The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands (31 July, 2007)

  C Ospelt, M Kurowska-Stolarska, M Neidhart, B A Michel, R E Gay, S Laufer, S Gay
• Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women (31 July, 2007)

  K H Costenbader, D Feskanich, M Holmes, E W Karlson, E Benito-Garcia
• EULAR evidence-based recommendations for the management of fibromyalgia syndrome (20 July, 2007) Free

  S F Carville, S Arendt-Nielsen, H Bliddal, F Blotman, J C Branco, D Buskila, J A P Da Silva, B Danneskiold-Samsøe, F Dincer, C Henriksson, K G Henriksson, E Kosek, K Longley, G M McCarthy, S Perrot, M Puszczewicz, P Sarzi-Puttini, A Silman, M Späth, E H Choy
• Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis (20 July, 2007)

  B Vander Cruyssen, L Nogueira, J Van Praet, D Deforce, D Elewaut, G Serre, F De Keyser
• Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy (5 October, 2007)

  M C Genovese, M Schiff, M Luggen, J-C Becker, R Aranda, J Teng, T Li, N Schmidely, M Le Bars, M Dougados